DS-2325a
Small molecule
Daiichi SankyoDS-2325a is one of 6 small molecule programs targeting Netherton syndrome. It is currently in development.
1
Indications
3
Total Trials
0
Active Trials
5
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
15 competitors in Netherton Syndrome
#DrugCompanyPhaseTrials
1Elidel
BBausch Health Americas, Inc.
Approved
Humira
CCelltrion
Phase 2
Spevigo
Boehringer IngelheimPhase 2
Dupixent
AAzienda U.S.L. 1 di Massa e Carrara
Phase 2
Stool Collect
AAssistance Publique - Hôpitaux de Paris
Preclinical
DS-2325a
Daiichi SankyoPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Netherton syndrome1 trial
Intravenous1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for DS-2325a. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Company